抗体

单克隆抗体是由单个B 淋巴细胞克隆所分泌的抗体，由于B 淋巴细胞只能产生一种专有的、针对一种抗原决定簇的抗体，所以具有理化性质高度专一、生物活性单一、与抗原结合特异性强等特点。因此，它也被形象地被称为“生物导弹”，现有的抗体药物大多属于此类抗体。近年来，单克隆抗体药物迅速发展，并逐渐成为生物医药领域发展的主要方向。

TargetMol可为您提供 xnum 多种抗体抑制剂，满足您的实验需求。TargetMol始终致力于服务“科研人员”，将热门的研究报道和产品推送给各位科研人员。

Cat. No.	Product Name	CAS No.	Purity	Chemical Structure
T9920	Evolocumab 依洛尤单抗	1256937-27-5	98%	Evolocumab
T9920	Evolocumab 是人源化单克隆抗体PCSK9的抑制剂。它与循环的 PCSK9 蛋白结合，使得PCSK9与 LDLR 结合受到抑制。它可用研究于高胆固醇血症以及动脉粥样硬化性心血管疾病的研究。			Evolocumab
T9923	Nimotuzumab 尼妥珠单抗	828933-51-3	95.00%
T9923	Nimotuzumab 是一种针对表皮生长因子受体 EGFR 的人源化治疗性单克隆抗体。
T36653	Anti-SARS-80R mAb Anti-SARS-80R mAb		98%	Anti-SARS-80R mAb
T36653	Anti-SARS-80R mAb (SARS-80R) is a human IgG1 monoclonal antibody that is derived from CHO cells. Its main function is to selectively bind to the Spike (S1) prote...			Anti-SARS-80R mAb
T36654	Anti-SARS-CoV-2 Spike mAb (CR3022) Anti-SARS-CoV-2 Spike mAb (CR3022)		98%	Anti-SARS-CoV-2 Spike mAb (CR3022)
T36654	Anti-SARS-CoV-2 Spike mAb (CR3022) is a human monoclonal IgG1 antibody derived from CHO cells. It specifically targets the S1 domain of the Spike protein in both...			Anti-SARS-CoV-2 Spike mAb (CR3022)
T36651	Anti-MERS-2E6 mAb Anti-MERS-2E6 mAb		98%	Anti-MERS-2E6 mAb
T36651	Anti-MERS-2E6 mAb (MERS-2E6), a human IgG1 neutralizing antibody, is expressed in CHO cells. It effectively competes with the virus Spike protein for binding to ...			Anti-MERS-2E6 mAb
T36655	Anti-Spike-RBD mAb Anti-Spike-RBD mAb		98%	Anti-Spike-RBD mAb
T36655	Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of spike protein and ACE2 is a potential therapeutic approach f...			Anti-Spike-RBD mAb
T9922	Matuzumab 马妥珠单抗	339186-68-4	98%	Matuzumab
T9922	Matuzumab 是一种用于癌症治疗的人源化单克隆抗体。它对 EGFR 具有高亲和力，通常与恶性肿瘤中血管的生长有关，从而促进肿瘤的生长和存活。			Matuzumab
T35389	Sarilumab (anti-IL-6Rα) Sarilumab (anti-IL-6Rα)		98%	Sarilumab (anti-IL-6Rα)
T35389	Sarilumab (anti-IL-6Rα)是人源anti-IL-6Rα单克隆抗体，与膜结合的和可溶性的IL-6Rα以高亲和力结合。MW: 144.13 KD。			Sarilumab (anti-IL-6Rα)
T36656	Anti-Spike-RBD Single Domain mAb Anti-Spike-RBD Single Domain mAb		98%	Anti-Spike-RBD Single Domain mAb
T36656	The Anti-Spike-RBD Single Domain mAb is a monoclonal antibody derived from CHO cells in Alpaca. It is composed of VHH-huFc and exhibits a strong affinity for the...			Anti-Spike-RBD Single Domain mAb
T12706	Reslizumab 化合物 T12706	241473-69-8	98%
T12706	Reslizumab is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma.
T9931	Meplazumab 化合物meplazumab	2413715-21-4	98%	meplazumab
T9931	meplazumab 是一种人源化抗 CD147 抗体，作为 COVID-19 肺炎患者的附加疗法。			meplazumab
T36652	Anti-MERS-3A1 mAb Anti-MERS-3A1 mAb		98%	Anti-MERS-3A1 mAb
T36652	Anti-MERS-3A1 mAb (MERS-3A1) is a high-affinity human monoclonal IgG1 antibody derived from CHO cells. It effectively inhibits the interaction between the MERS-C...			Anti-MERS-3A1 mAb
T35396	Spartalizumab (anti-PD-1) Spartalizumab (anti-PD-1)		98%	Spartalizumab (anti-PD-1)
T35396	Spartalizumab (anti-PD-1)是一种针对PD-1的人源IgG4抗体，抑制PD-L1和PD-L2与PD-1的结合。PDR001可与PD-1以高亲和力结合，抑制其生物活性；MW: 145.8 KD。			Spartalizumab (anti-PD-1)
T76559	Survodutide 化合物Survodutide	2805997-46-8	99.83%
T76559	Survodutide (BI 456906) 是一种胰高血糖素和胰高血糖素样肽 1 (GLP-1) 受体 (GLP Receptor) 双重激动剂,可降低 HbA1c16 型糖尿病的体重。
T9908	Pembrolizumab 派姆單抗	1374853-91-4	99.70%	Pembrolizumab
T9908	Pembrolizumab 是一种抑制 PD-1 受体的人源化单克隆抗体，是一个 HER2 二聚化抑制剂类，它会削弱 HER2 与 HER 家族其他成员结合的能力。			Pembrolizumab
T9921	Infliximab 英夫利昔单抗	170277-31-3	99.70%
T9921	Infliximab 是一种与 TNF-α特异性结合的嵌合单克隆 IgG1 抗体，可阻止 TNF-α与 TNFR1和 TNFR2 的相互作用，用于治疗克罗恩病和类风湿性关节炎。
T9913	Ustekinumab 尤特克单抗	815610-63-0	99.70%
T9913	Ustekinumab 是一种人源化靶向抗IL-12/IL-23的单克隆 IgG1κ 抗体。
T9906	Ipilimumab 伊匹单抗	477202-00-9	99.60%
T9906	Ipilimumab 是全人类单克隆抗体 IgG1κ，能够抗 CTLA-4。其中CTLA-4是一种由活化的 T 细胞产生的免疫抑制分子。
T9911	Tocilizumab 托珠单抗	375823-41-9	99.50%
T9911	Tocilizumab 是抗人白细胞介素-6 受体 (IL-6R) 的中和抗体，能够阻碍 IL-6 与 IL-6R 的结合，进而抑制经典和反式信号。它可用于研究类风湿性关节炎，对重症 COVID-19 冠状病毒病方面的研究具有显著效果。
T9930	Secukinumab 苏金单抗	875356-43-7	99.10%	Secukinumab
T9930	Secukinumab 是一种完全人源化的单克隆抗 IL-17A 抗体，是一个被美国食品和药物管理局批准用于治疗中度至重度斑块型银屑病的抗体。			Secukinumab